CoChat

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

Galon, Jerome, Mlecnik, Bernhard, Marliot, Florence, Ou, Fang-Shu, Bifulco, Carlo Bruno, Lugli, Alessandro, Zlobec, Inti, Rau, Tilman T., Hartmann, Arndt, Masucci, Giuseppe V., Zavadova, Eva, Ohashi, Pam, Roehrl, Michael H. A., Kawakami, Yutaka, Torigoe, Toshihiko, Ascierto, Paolo Antonio, Marincola, Franco, Sargent, Daniel J., Fox, Bernard A., Pages, Franck · 2016 · Journal of Clinical Oncology
Cited by 87

The DOI matches its Crossref record.

Abstract

3500 Background: Mounting evidence indicates an enhanced lymphocytic reaction as an informative prognostic indicator in colon cancer (CC). The IM methodology has been defined to quantify the in situ immune infiltrate. Methods: A Society for Immunotherapy of Cancer-led international consortium of 23 pathology expert centers from 17 countries was initiated to evaluate the standardized IM assay in routine clinical settings. Patient (pt) eligibility criteria were CC Stages I/II/III and no neo-adjuvant treatment. 1336 pts split into a training set (TS) and internal validation set (IVS) were quantified for IM using standardized procedure, immunohistochemistry using CD3 and CD8 antibodies, and quantification using digital pathology on whole slide section of primary CCs. Statistical analysis plan was pre-defined and all statistical analyses performed by blinded external statisticians. Primary study endpoint was time-to-recurrence (TTR); analyses were by Cox models stratified by enrolling center. Results: Median recurrent follow-up duration across centers was 5.9 years. Overall pts: 51% Male, median age 69 years, 19%/56%/25% stage I/II/III. Among pts with Stages I/II/III CC, in the TS TTR was shorter among 332 pts (48.1%) with Low-IM CC vs. 358 pts with High-IM CC (HR (95% CI), 0.35 (0.23-0.52); P < 0.0001). In the IVS (630 pts) TTR was also shorter among 303 pts with Low-IM CC vs. 327 pts with High-IM CC (HR (95% CI), 0.54 (0.34-0.84); P = 0.006). In both groups, results were independent of pt age, sex, tumor stage and sidedness. Among pts with Stage II CC, the difference in TTR between Low and High-IM was significant both in the TS (HR (95% CI), 0.27 (0.14-0.51); P < 0.0001) and in the IVS (HR (95% CI), 0.46 (0.24-0.87) P = 0.014); multivariate results similar (TS HR (95% CI), 0.28 (0.14-0.54); P < 0.0001) and IVS HR (95% CI), 0.46 (0.24-0.87); P = 0.0142)). Reproducibility of the standardized IM assay was validated across centers. Conclusions: The primary endpoint of the worldwide pre-specified IM study was reached. TTR was significantly longer in pts stages I/II/III with High-IM. Low-IM identified a subgroup of patients with high-risk stage II CC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.3500

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 87

Metadata

Authors
Galon, J., Mlecnik, B., Marliot, F., Ou, F.-S., Bifulco, C. B., Lugli, A., Zlobec, I., Rau, T. T., Hartmann, A., Masucci, G. V., Zavadova, E., Ohashi, P., Roehrl, M. H. A., Kawakami, Y., Torigoe, T., Ascierto, P. A., Marincola, F., Sargent, D. J., Fox, B. A., & Pages, F.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
3500-3500
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2523845392
Cited by
87
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.3500
The paper
Galon, J., Mlecnik, B., Marliot, F., Ou, F.-S., Bifulco, C. B., Lugli, A., Zlobec, I., Rau, T. T., Hartmann, A., Masucci, G. V., Zavadova, E., Ohashi, P., Roehrl, M. H. A., Kawakami, Y., Torigoe, T., Ascierto, P. A., Marincola, F., Sargent, D. J., Fox, B. A., & Pages, F. (2016). Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.3500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.